Blood Res 2022; 57(3):
Published online September 30, 2022
https://doi.org/10.5045/br.2022.2022095
© The Korean Society of Hematology
Correspondence to : Myung-Geun Shin
Department of Laboratory Medicine, Chonnam National University and Chonnam National University Hwasun Hospital, 322, Seoyang-ro, Hwasun-eup, Hwasun-gun, Jeonnam 58128, Korea
E-mail: mgshin@chonnam.ac.kr
#These authors contributed equally to this work.
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
Genetic mutations that occur in blood cancer can be broadly classified into nucleotide sequence mutations, including duplications or deletions; fusion gene mutations; and abnormal gene overexpression. Among these genetic mutations, gene fusion not only plays an important role in the development of blood cancers such as leukemia, it is also important as an essential marker for diagnosis, risk assessment, optimal treatment selection, and residual lesion detection. Most clinical hematology laboratories use conventional cytogenetic testing, fluorescent in situ hybridization (FISH), and multiplex reverse transcriptase-PCR to detect gene fusion mutations [1, 2]. However, the above methods currently used have great limitations in detecting various gene fusions that occur in blood cancer. To overcome these shortcomings, RNA sequencing (RNA-seq) methods are being introduced in clinical laboratories. However, the RNA-seq method is not widely used due to the complexity of the data processing and interpretation. The authors developed a targeted RNA-seq panel (KBB-RNAseq NGS-Leukemia- PHB; KBlueBio Inc., Hwasun, Korea) and bioinformatics pipeline that can be used for targeted RNA-seq to detect gene fusions, sequence variants, and altered gene expression, and is more convenient than traditional RNA-seq methods for use in clinical hematology laboratories [3]. The targeted RNA-seq panel and analysis pipeline, developed using information technology with an automated reporting system and commercialized by the authors, was subjected to a comparative evaluation with a commercialized targeted RNA- seq panel (ArcherTM FusionPlexTM Heme Panel version 2, Archer DX, Boulder, CA, USA) using leukemia patient samples.
The targeted RNA-seq system for detecting gene fusions in blood cancers developed by the authors comprised 84 genes, including the self-discovered prohibitin as a companion diagnostic marker for hematological malignancies, and was optimized by MiseqDx (Illumina, San Diego, CA, USA) after library preparation using the capture hybridization method. The test performance of this system was evaluated using bone marrow specimens that were collected when diagnosing 93 patients with leukemia [15 with acute myeloid leukemia (AML), 35 with adult B-acute lymphoid leukemia (B-ALL), 30 with childhood B-ALL, and 13 with T-acute lymphoid leukemia (T-ALL)]. Out of all 93 leukemia patients, tier 1 or tier 2 gene fusions were observed in 72 (77%) patients. Fusion gene mutations were detected in 83% (25/30) of the childhood B-ALL and 94% of the adult B-ALL samples (33/35). In patients with AML or T-ALL, fusion gene mutations were found in 53% (8/15) and 46% (6/13), respectively (Fig. 1).
A commercial targeted RNA-seq analysis system developed by constructing a cDNA library for specific genes using anchored multiplex PCR [3] was compared to the detection system (KBB-RNAseq NGS-Leukemia-PHB) developed by the authors [4]. For this comparative evaluation, four cases of B-ALL, two cases of AML, and one case each of acute promyelocytic leukemia and T-ALL were used. The results of the two analysis systems were consistent for seven of the eight comparatively evaluated patients, however, B-ALL accompanied by an
Table 1 Comparative evaluation with a commercially available targeted RNA-seq panel.
Sample no. | Diagnosis | Multiplex RT-PCR or FISH | Commercial targeted RNA-seq system [4] | Breakpoint | Our targeted RNA-seq system [3] | Breakpoint |
---|---|---|---|---|---|---|
1 | APL | chr15:74325755 | chr15:74325755 | |||
chr17:38504568 | chr17:38504568 | |||||
2 | B-ALL | chr22:23524426 | chr22:23524426 | |||
chr9:133729451 | chr9:133729451 | |||||
chr22:23595986 | ||||||
chr9:133589842 | ||||||
3 | AML | chr21:36231771 | chr21:36231771 | |||
chr8:93029591 | chr8:93029591 | |||||
chr21:36231771 | chr21:36231771 | |||||
chr8:93074855 | chr8:93074937 | |||||
chr21:36231771 | chr21:36231875 | |||||
chr8:93074937 | chr8:93074774 | |||||
4 | B-ALL | chr12:12022900 | chr21:36265260 | |||
chr21:36265263 | chr12:12022903 | |||||
chr12:12022903 | chr21:36259393 | |||||
chr21:36265260 | chr12:1202290 | |||||
chr12:12022903 | ||||||
chr21:36259393 | ||||||
chr12:12022903 | ||||||
chr21:36340571 | ||||||
5 | B-ALL | Negative | chrX:1655814 | chrX:1655814 | ||
chrX:1331530 | chrX:1331529 | |||||
chr3:71739161 | ||||||
chr3:71542706 | ||||||
6 | B-ALL | Negative | Negative | chr14:106329453 | ||
chrX:1351126 | ||||||
chr14:106322373 | ||||||
chrX:1351121 | ||||||
chr14:106330849 | ||||||
chrX:1351119 | ||||||
7 | AML | chr16:67116211 | ||||
chr16:15814908 | ||||||
chr16:67116242 | ||||||
chr16:15814908 | ||||||
8 | T-ALL | Negative | chr11:85692172 | chr11:85692172 | ||
chr10:21875223 | chr10:21875223 | |||||
chr11:85689133 | chr11:85687725 | |||||
chr10:21875228 | chr10:21827841 | |||||
chr11:85692184 | chr11:85670103 | |||||
chr10:21827830 | chr10:21827841 |
Abbreviations: FISH, fluorescence in situ hybridization; RNA-seq, RNA sequencing; RT-PCR, reverse transcriptase-PCR.
Information technology (IT)-based data analytics software (NGeneAnalySys, NGeneBio, Seoul, Korea) was used to analyze the data produced by the next-generation sequencing (NGS) equipment using the RNA-seq panel (KBB-RNAseq NGS-Leukemia-PHB) developed by the authors (Supplementary Fig. 1). After selecting the data generated by the NGS equipment, the data are uploaded to the analysis server, the panel type is selected, and an automatic analysis is performed. The status of the analysis can be checked in real-time, as can the list of mutations found by the automatic analysis and the correct classification of the results according to the importance of the mutations. Variation filtering using annotation information is performed, a clinical report is first prepared, and a final report is issued after confirming the patient, test information, and the type and importance of the detected mutation. Information (VAF, HGVS, sequence, COSMIC, population, and IGV information check), a mutation analysis according to guidelines such as association for molecular pathology, a quality control report, and a customizable clinical report are provided.
In conclusion, our targeted RNA-seq system accurately and efficiently detected various fusion gene mutations that occur in acute leukemia. Importantly, our targeted RNA-seq panel detected the fusion gene mutations that cause Ph-like B-ALL more accurately than a commercially-available targeted system.
The authors would like to thank Dr. Veena Selvaratnam, a consultant hematologist from Hospital Ampang, Malaysia, for providing clinical information on other confirmed cases in Malaysia and the medical team involved in the management of this patient. All authors contributed equally to the writing of this manuscript.
No potential conflicts of interest relevant to this article were reported.
Blood Res 2022; 57(3): 235-238
Published online September 30, 2022 https://doi.org/10.5045/br.2022.2022095
Copyright © The Korean Society of Hematology.
Young Eun Lee1,2#, Ju Heon Park1#, Ha Jin Lim1, Hye Ran Kim3, Jong Hee Shin1, Myung Geun Shin1,2
1Department of Laboratory Medicine, 2BioMedical Sciences Graduate Program (BMSGP), Chonnam National University and Chonnam National University Hwasun Hospital, Hwasun, 3College of Korean Medicine, Dongshin University, Naju, Korea
Correspondence to:Myung-Geun Shin
Department of Laboratory Medicine, Chonnam National University and Chonnam National University Hwasun Hospital, 322, Seoyang-ro, Hwasun-eup, Hwasun-gun, Jeonnam 58128, Korea
E-mail: mgshin@chonnam.ac.kr
#These authors contributed equally to this work.
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
Genetic mutations that occur in blood cancer can be broadly classified into nucleotide sequence mutations, including duplications or deletions; fusion gene mutations; and abnormal gene overexpression. Among these genetic mutations, gene fusion not only plays an important role in the development of blood cancers such as leukemia, it is also important as an essential marker for diagnosis, risk assessment, optimal treatment selection, and residual lesion detection. Most clinical hematology laboratories use conventional cytogenetic testing, fluorescent in situ hybridization (FISH), and multiplex reverse transcriptase-PCR to detect gene fusion mutations [1, 2]. However, the above methods currently used have great limitations in detecting various gene fusions that occur in blood cancer. To overcome these shortcomings, RNA sequencing (RNA-seq) methods are being introduced in clinical laboratories. However, the RNA-seq method is not widely used due to the complexity of the data processing and interpretation. The authors developed a targeted RNA-seq panel (KBB-RNAseq NGS-Leukemia- PHB; KBlueBio Inc., Hwasun, Korea) and bioinformatics pipeline that can be used for targeted RNA-seq to detect gene fusions, sequence variants, and altered gene expression, and is more convenient than traditional RNA-seq methods for use in clinical hematology laboratories [3]. The targeted RNA-seq panel and analysis pipeline, developed using information technology with an automated reporting system and commercialized by the authors, was subjected to a comparative evaluation with a commercialized targeted RNA- seq panel (ArcherTM FusionPlexTM Heme Panel version 2, Archer DX, Boulder, CA, USA) using leukemia patient samples.
The targeted RNA-seq system for detecting gene fusions in blood cancers developed by the authors comprised 84 genes, including the self-discovered prohibitin as a companion diagnostic marker for hematological malignancies, and was optimized by MiseqDx (Illumina, San Diego, CA, USA) after library preparation using the capture hybridization method. The test performance of this system was evaluated using bone marrow specimens that were collected when diagnosing 93 patients with leukemia [15 with acute myeloid leukemia (AML), 35 with adult B-acute lymphoid leukemia (B-ALL), 30 with childhood B-ALL, and 13 with T-acute lymphoid leukemia (T-ALL)]. Out of all 93 leukemia patients, tier 1 or tier 2 gene fusions were observed in 72 (77%) patients. Fusion gene mutations were detected in 83% (25/30) of the childhood B-ALL and 94% of the adult B-ALL samples (33/35). In patients with AML or T-ALL, fusion gene mutations were found in 53% (8/15) and 46% (6/13), respectively (Fig. 1).
A commercial targeted RNA-seq analysis system developed by constructing a cDNA library for specific genes using anchored multiplex PCR [3] was compared to the detection system (KBB-RNAseq NGS-Leukemia-PHB) developed by the authors [4]. For this comparative evaluation, four cases of B-ALL, two cases of AML, and one case each of acute promyelocytic leukemia and T-ALL were used. The results of the two analysis systems were consistent for seven of the eight comparatively evaluated patients, however, B-ALL accompanied by an
Table 1 . Comparative evaluation with a commercially available targeted RNA-seq panel..
Sample no. | Diagnosis | Multiplex RT-PCR or FISH | Commercial targeted RNA-seq system [4] | Breakpoint | Our targeted RNA-seq system [3] | Breakpoint |
---|---|---|---|---|---|---|
1 | APL | chr15:74325755 | chr15:74325755 | |||
chr17:38504568 | chr17:38504568 | |||||
2 | B-ALL | chr22:23524426 | chr22:23524426 | |||
chr9:133729451 | chr9:133729451 | |||||
chr22:23595986 | ||||||
chr9:133589842 | ||||||
3 | AML | chr21:36231771 | chr21:36231771 | |||
chr8:93029591 | chr8:93029591 | |||||
chr21:36231771 | chr21:36231771 | |||||
chr8:93074855 | chr8:93074937 | |||||
chr21:36231771 | chr21:36231875 | |||||
chr8:93074937 | chr8:93074774 | |||||
4 | B-ALL | chr12:12022900 | chr21:36265260 | |||
chr21:36265263 | chr12:12022903 | |||||
chr12:12022903 | chr21:36259393 | |||||
chr21:36265260 | chr12:1202290 | |||||
chr12:12022903 | ||||||
chr21:36259393 | ||||||
chr12:12022903 | ||||||
chr21:36340571 | ||||||
5 | B-ALL | Negative | chrX:1655814 | chrX:1655814 | ||
chrX:1331530 | chrX:1331529 | |||||
chr3:71739161 | ||||||
chr3:71542706 | ||||||
6 | B-ALL | Negative | Negative | chr14:106329453 | ||
chrX:1351126 | ||||||
chr14:106322373 | ||||||
chrX:1351121 | ||||||
chr14:106330849 | ||||||
chrX:1351119 | ||||||
7 | AML | chr16:67116211 | ||||
chr16:15814908 | ||||||
chr16:67116242 | ||||||
chr16:15814908 | ||||||
8 | T-ALL | Negative | chr11:85692172 | chr11:85692172 | ||
chr10:21875223 | chr10:21875223 | |||||
chr11:85689133 | chr11:85687725 | |||||
chr10:21875228 | chr10:21827841 | |||||
chr11:85692184 | chr11:85670103 | |||||
chr10:21827830 | chr10:21827841 |
Abbreviations: FISH, fluorescence in situ hybridization; RNA-seq, RNA sequencing; RT-PCR, reverse transcriptase-PCR..
Information technology (IT)-based data analytics software (NGeneAnalySys, NGeneBio, Seoul, Korea) was used to analyze the data produced by the next-generation sequencing (NGS) equipment using the RNA-seq panel (KBB-RNAseq NGS-Leukemia-PHB) developed by the authors (Supplementary Fig. 1). After selecting the data generated by the NGS equipment, the data are uploaded to the analysis server, the panel type is selected, and an automatic analysis is performed. The status of the analysis can be checked in real-time, as can the list of mutations found by the automatic analysis and the correct classification of the results according to the importance of the mutations. Variation filtering using annotation information is performed, a clinical report is first prepared, and a final report is issued after confirming the patient, test information, and the type and importance of the detected mutation. Information (VAF, HGVS, sequence, COSMIC, population, and IGV information check), a mutation analysis according to guidelines such as association for molecular pathology, a quality control report, and a customizable clinical report are provided.
In conclusion, our targeted RNA-seq system accurately and efficiently detected various fusion gene mutations that occur in acute leukemia. Importantly, our targeted RNA-seq panel detected the fusion gene mutations that cause Ph-like B-ALL more accurately than a commercially-available targeted system.
The authors would like to thank Dr. Veena Selvaratnam, a consultant hematologist from Hospital Ampang, Malaysia, for providing clinical information on other confirmed cases in Malaysia and the medical team involved in the management of this patient. All authors contributed equally to the writing of this manuscript.
No potential conflicts of interest relevant to this article were reported.
Table 1 . Comparative evaluation with a commercially available targeted RNA-seq panel..
Sample no. | Diagnosis | Multiplex RT-PCR or FISH | Commercial targeted RNA-seq system [4] | Breakpoint | Our targeted RNA-seq system [3] | Breakpoint |
---|---|---|---|---|---|---|
1 | APL | chr15:74325755 | chr15:74325755 | |||
chr17:38504568 | chr17:38504568 | |||||
2 | B-ALL | chr22:23524426 | chr22:23524426 | |||
chr9:133729451 | chr9:133729451 | |||||
chr22:23595986 | ||||||
chr9:133589842 | ||||||
3 | AML | chr21:36231771 | chr21:36231771 | |||
chr8:93029591 | chr8:93029591 | |||||
chr21:36231771 | chr21:36231771 | |||||
chr8:93074855 | chr8:93074937 | |||||
chr21:36231771 | chr21:36231875 | |||||
chr8:93074937 | chr8:93074774 | |||||
4 | B-ALL | chr12:12022900 | chr21:36265260 | |||
chr21:36265263 | chr12:12022903 | |||||
chr12:12022903 | chr21:36259393 | |||||
chr21:36265260 | chr12:1202290 | |||||
chr12:12022903 | ||||||
chr21:36259393 | ||||||
chr12:12022903 | ||||||
chr21:36340571 | ||||||
5 | B-ALL | Negative | chrX:1655814 | chrX:1655814 | ||
chrX:1331530 | chrX:1331529 | |||||
chr3:71739161 | ||||||
chr3:71542706 | ||||||
6 | B-ALL | Negative | Negative | chr14:106329453 | ||
chrX:1351126 | ||||||
chr14:106322373 | ||||||
chrX:1351121 | ||||||
chr14:106330849 | ||||||
chrX:1351119 | ||||||
7 | AML | chr16:67116211 | ||||
chr16:15814908 | ||||||
chr16:67116242 | ||||||
chr16:15814908 | ||||||
8 | T-ALL | Negative | chr11:85692172 | chr11:85692172 | ||
chr10:21875223 | chr10:21875223 | |||||
chr11:85689133 | chr11:85687725 | |||||
chr10:21875228 | chr10:21827841 | |||||
chr11:85692184 | chr11:85670103 | |||||
chr10:21827830 | chr10:21827841 |
Abbreviations: FISH, fluorescence in situ hybridization; RNA-seq, RNA sequencing; RT-PCR, reverse transcriptase-PCR..